VJHemOnc is committed to improving our service to you

EHA 2019 | ANCHOR study updates

VJHemOnc is committed to improving our service to you

Enrique Ocio

Enrique Ocio, MD, PhD, University Hospital of Salamanca, Salamanca, Spain, gives updates on the ANCHOR study (NCT03481556)O, where melflufen and dexamethasone plus bortezomib or daratumumab is administered in patients with relapsed/refractory multiple myeloma. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter